In a report released today, Gil Blum from Needham reiterated a Buy rating on Artiva Biotherapeutics, Inc., with a price target of $18.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Gil Blum has given his Buy rating due to a combination of factors surrounding Artiva Biotherapeutics, Inc.’s recent clinical results. The company presented promising early safety and translational data from their alloNK treatment in autoimmune patients, highlighting an impressive safety profile with no reports of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), and only a single grade 3 infection reported.
Additionally, the data on B-cell aplasia, showing around three months of suppression, suggests a competitive edge over other treatment modalities like CAR-Ts or TCEs. With the anticipation of clinical efficacy results from over 15 rheumatoid arthritis patients and a regulatory update expected in the first half of 2026, these findings are seen as a strong indicator of future success, supporting the Buy rating.
According to TipRanks, Blum is a 4-star analyst with an average return of 4.7% and a 39.76% success rate. Blum covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Celcuity, and Autolus Therapeutics.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.